Does UBROGEPANT Cause Mobility decreased? 5 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Mobility decreased have been filed in association with UBROGEPANT (UBRELVY). This represents 0.2% of all adverse event reports for UBROGEPANT.
5
Reports of Mobility decreased with UBROGEPANT
0.2%
of all UBROGEPANT reports
0
Deaths
2
Hospitalizations
How Dangerous Is Mobility decreased From UBROGEPANT?
Of the 5 reports, 2 (40.0%) required hospitalization.
Is Mobility decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for UBROGEPANT. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does UBROGEPANT Cause?
Drug ineffective (656)
Migraine (399)
Nausea (210)
Headache (204)
Off label use (132)
Dizziness (111)
Fatigue (92)
Somnolence (87)
Therapeutic product effect incomplete (69)
Vomiting (67)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which UBROGEPANT Alternatives Have Lower Mobility decreased Risk?
UBROGEPANT vs ULIPRISTAL
UBROGEPANT vs UMBRALISIB
UBROGEPANT vs UMECLIDINIUM
UBROGEPANT vs UMECLIDINIUM\VILANTEROL TRIFENATATE
UBROGEPANT vs UMIFENOVIR